| | No recurrence | Recurrence | P |
| Number of patients, (%) | 173 (70.9) | 71 (29.1) | | Age (years), mean ± std, IQR | 66.3 ± 6.56, 9 | 65.9 ± 6.36, 11 | 0.527† | PSA (ng/mL), mean ± std, IQR | 8.37 ± 3.23, 4.29 | 9.99 ± 4.35, 5.20 | 0.005†* | PSA density (ng/mL2), mean ± std, IQR | 0.29 ± 0.25, 0.18 | 0.46 ± 0.57, 0.27 | 0.002†* | Preoperative Gleason score, n (%) | | | 0.015‡* | ≤6 | 71 (41.0) | 16 (22.5) | | 7 | 79 (45.7) | 39 (54.9) | | ≥8 | 23 (13.3) | 16 (22.5) | | Pathological Gleason score, n (%) | | | 0.423‡ | ≤6 | 65 (37.6) | 21 (29.6) | | 7 | 78 (45.1) | 34 (47.9) | | ≥8 | 30 (17.3) | 16 (22.5) | | Clinical stage, n (%) | | | 0.201‡ | T1c | 134 (77.5) | 47 (66.2) | | T2a | 29 (16.8) | 16 (22.5) | | T2b | 8 (4.6) | 8 (11.3) | | T2c | 2 (1.2) | 0 (0) | | Pathological stage, n (%) | | | 0.001‡* | T2a | 19 (11.0) | 6 (8.45) | | T2b | 7 (4.05) | 1 (1.41) | | T2c | 104 (60.1) | 38 (53.5) | | T3a | 36 (20.8) | 11 (15.5) | | T3b | 7 (4.05) | 15 (21.1) | | Extracapsular disease, n (%) | | | 0.064‡ | No | 130 (75.1) | 45 (63.4) | | Yes | 43 (24.9) | 26 (36.6) | | Surgical margins, n (%) | | | 0.021‡* | Negative | 126 (72.8) | 41 (57.7) | | Positive | 47 (27.2) | 30 (42.3) | | Seminal vesicles invasion, n (%) | | | <0.001‡* | No | 166 (96.0) | 56 (78.9) | | Yes | 7 (4.05) | 15 (21.1) | | Lymph nodes invasion, n (%) | | | <0.001‡* | No | 83 (100.0) | 39 (55.7) | | Yes | 0 (0) | 31 (44.3) | |
|
|